MedPath

Dimethyltryptamine

Generic Name
Dimethyltryptamine
Drug Type
Small Molecule
Chemical Formula
C12H16N2
CAS Number
61-50-7
Unique Ingredient Identifier
WUB601BHAA
Background

An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.

Indication

Some people use this compound as a psychedelic inducing agent.

Clinical Trials
Related News

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Phase 3
Active, not recruiting
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2021-03-09
Last Posted Date
2025-03-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
185
Registration Number
NCT04788615
Locations
🇪🇸

Novartis Investigative Site, Valencia, Spain

Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

Early Phase 1
Completed
Conditions
Emotions
Mood
Empathy
Cognitive Function 1, Social
Interventions
Drug: Placebo (Harmine)
Drug: Placebo (DMT)
First Posted Date
2021-01-20
Last Posted Date
2022-10-04
Lead Sponsor
Psychiatric University Hospital, Zurich
Target Recruit Count
34
Registration Number
NCT04716335
Locations
🇨🇭

Psychiatric University Hospital, Zürich, Switzerland

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

Phase 1
Active, not recruiting
Conditions
Major Depressive Disorder
Depression
Interventions
First Posted Date
2021-01-15
Last Posted Date
2024-12-12
Lead Sponsor
Yale University
Target Recruit Count
30
Registration Number
NCT04711915
Locations
🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Clinical Study of GH001 in Depression

Phase 1
Completed
Conditions
Major Depressive Disorder
Treatment Resistant Depression
Depression
Interventions
First Posted Date
2021-01-07
Last Posted Date
2023-08-15
Lead Sponsor
GH Research Ireland Limited
Target Recruit Count
16
Registration Number
NCT04698603
Locations
🇳🇱

Clinical Trial Site, Maastricht, Netherlands

Safety of GH001 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2020-11-23
Last Posted Date
2023-08-15
Lead Sponsor
GH Research Ireland Limited
Target Recruit Count
22
Registration Number
NCT04640831
Locations
🇳🇱

Clinical Trial Site, Maastricht, Netherlands

Effects of Dimethyltryptamine in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Saline
First Posted Date
2020-04-20
Last Posted Date
2022-10-12
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
31
Registration Number
NCT04353024
Locations
🇨🇭

University Hospital Basel, Basel, Basel-Stadt BS, Switzerland

Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).

Not Applicable
Conditions
Multiple Sclerosis
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis, Relapsing-Remitting
Interventions
First Posted Date
2020-02-07
Last Posted Date
2020-10-19
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
130
Registration Number
NCT04260711
Locations
🇳🇱

Amsterdam UMC, Amsterdam, Netherlands

Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)

Phase 3
Recruiting
Conditions
Multiple Sclerosis
Interventions
Other: DMT withdrawal
First Posted Date
2018-08-31
Last Posted Date
2023-10-24
Lead Sponsor
Rennes University Hospital
Target Recruit Count
250
Registration Number
NCT03653273
Locations
🇫🇷

Hôpital Saint Vincent de Paul, Lille, France

🇫🇷

Hospices Civils Lyon, Lyon, France

🇫🇷

CHU Montpellier, Montpellier, France

and more 24 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy